

Iman Abou Dalle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5516255/publications.pdf>

Version: 2024-02-01

16
papers

304
citations

1307594

7
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

403
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
2	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , 2020, 26, 6475-6482.	7.0	40
3	Prognostic significance of baseline <i>FLT3</i> mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. <i>American Journal of Hematology</i> , 2019, 94, 984-991.	4.1	32
4	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline <i>DDX41</i> mutation. <i>American Journal of Hematology</i> , 2020, 95, 227-229.	4.1	29
5	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	4.1	26
6	Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. <i>Cancer Medicine</i> , 2019, 8, 6559-6565.	2.8	24
7	Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed <i>FLT3</i> -mutant acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 48.	6.2	22
8	20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2022, 28, 1004-1012.	7.0	12
9	The use of intrathecal chemotherapy and dexamethasone for secondary prevention of blinatumomab-related neurotoxicity. <i>Current Research in Translational Medicine</i> , 2021, 69, 103285.	1.8	7
10	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. <i>Haematologica</i> , 2021, 106, 0-0.	3.5	6
11	Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. <i>Cancer</i> , 2021, 127, 1894-1900.	4.1	5
12	Intrathecal methotrexate induced myelopathy, rare yet serious complication: A case report and review of the literature. <i>Current Research in Translational Medicine</i> , 2021, 69, 103296.	1.8	4
13	Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients. <i>Leukemia Research</i> , 2021, 105, 106568.	0.8	3
14	The Use of Voriconazole as Primary Prophylaxis for Invasive Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation: A Single Center's Experience. <i>Journal of Fungi (Basel)</i> , 2021, 6, 1000000.	0.0	0
15	Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Clinical Hematology International</i> , 2022, 4, 30-34.	1.7	1
16	First-Line Treatment of Hairy Cell Leukemia with Cladribine Followed by Rituximab Consolidation Significantly Improves Leukemia-Free Survival. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 564-566.	0.4	0